GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Cyclically Adjusted Revenue per Share

Actelion (Actelion) Cyclically Adjusted Revenue per Share : $0.00 (As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Actelion's adjusted revenue per share data for the fiscal year that ended in Dec. 2016 was $22.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2016.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-06), Actelion's current stock price is $ 277.1446. Actelion's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2016 was $0.00. Actelion's Cyclically Adjusted PS Ratio of today is .


Actelion Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Actelion's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Cyclically Adjusted Revenue per Share Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actelion's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Actelion's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Actelion's Cyclically Adjusted PS Ratio falls into.



Actelion Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Actelion's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2016 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2016 (Change)*Current CPI (Dec. 2016)
=22.001/99.3795*99.3795
=22.001

Current CPI (Dec. 2016) = 99.3795.

Actelion Annual Data

Revenue per Share CPI Adj_RevenuePerShare
200712 9.257 100.619 9.143
200812 10.469 101.324 10.268
200912 14.004 101.610 13.697
201012 16.400 102.138 15.957
201112 16.193 101.408 15.869
201212 15.882 100.968 15.632
201312 17.326 101.036 17.042
201412 17.272 100.704 17.045
201512 18.270 99.386 18.269
201612 22.001 99.380 22.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Actelion  (OTCPK:ALIOF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Actelion Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Actelion's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (Actelion) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016